STA Research assigns a Speculative Buy rating on NanoVibronix Inc., with a 12 month target price of $1.25 per share.
Based on the NanoVibronix Inc. stock (naov stock price) forecasts from 1 analysts, the average analyst target price for NanoVibronix Inc. (naov stock price) is $1.25 over the next 12 months. NanoVibronix Inc.’s average analyst rating is. Stock Target Advisor’s own stock analysis of NanoVibronix Inc. (naov stock price) is Bearish, which is based on 1 positive signal and 8 negative signals. At the last closing, NanoVibronix Inc.’s stock price was USD 0.69. NanoVibronix Inc.’s stock price has changed by +0.05% over the past week, +0.00% over the past month and -16.51% over the last year.
Through its subsidiary, NanoVibronix, Inc. (naov stock price) specialises in the production and marketing of noninvasive biological response-activating devices for biofilm prevention, wound healing, and pain management. Its main products include WoundShield, a patch-based therapeutic ultrasound device that promotes tissue regeneration and wound healing, PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasms, and joint contractures, and UroShield, an ultrasound-based product to prevent bacterial colonisation and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use. The business offers its goods directly to patients in the US, Israel, Europe, India, and other countries, as well as through distributor partnerships. Incorporated in 2003, NanoVibronix, Inc. (naov stock price) has its headquarters in Elmsford, New York.
What we like:
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
What we don’t like:
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Poor risk-adjusted returns
This company is delivering below median risk-adjusted returns to its peers. Even if it is outperforming on returns, the returns are unpredictable. Proceed with caution.
The total returns for this company are volatile and above the median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Overpriced compared to book value
The stock is trading high compared to its peers’ median on a price-to-book value basis.
Negative cash flow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector